|  |  |
| --- | --- |
| **Report title** | Monthly Finance Performance Report Month 01 – April 2022 |
| **Report from**  | Jonathan Wilson, Chief Financial Officer |
| **Prepared by** | Justin Betts, Deputy Chief Financial Officer  |
| **Link to strategic objectives** | Deliver financial sustainability as a Trust |

|  |
| --- |
| **Executive summary****Income and Expenditure** For April, the Trust is reporting:- * a £2.16m deficit year to date compared to a deficit plan of £2.39m, a £0.23m favourable variance.

* Clinical activity levels recorded in April compared to 2019/20 were 70% of A&E activity, 103% Elective, 94% Core Outpatients (excluding DGH or 86% inclusive), and 122% injections activity.
* Clinical income in month has been estimated based on draft guidance. National guidance in relation to the formal calculation of income linked to Elective Recovery Funding (ERF) has not been finalised.

**Capital Expenditure*** Capital spend during April totalled £0.5m, against a plan of £0.4m predominantly due to slippage of schemes form 2021/22 into 2022/23.
* Internal capital plans are being reviewed and prioritised via the Capital Planning and Oversight Committee given restricted resources in 2022/23.
* Formal confirmation of externally funded schemes is awaited including TIF schemes £8m, UTF £2.5m, and elements of Oriel within/out with the NCL ICS envelopes £14.9m.
 |
| **Quality implications**Patient safety has been considered in the allocation of budgets. |
| **Financial implications**Delivery of the financial control total will result in the Trust being eligible for additional benefits that will support its future development. |
| **Risk implications**Potential risks have been considered within the reported financial position and the financial risk register is discussed at the Audit Committee. |
| **Action Required/Recommendation**The board is asked to consider and discus the attached report. |
| **For Assurance** |  | **For decision** |  | **For discussion** | **✓** | **To note** | **✓** |